Montag & Associates’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Montag & Associates’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3	Closed	–	–	951
2022 Q3	$0	Hold	3	–	–	﹤0.01%	863
2022 Q2	$0	Hold	3	–	–	﹤0.01%	828
2022 Q1	$0	Hold	3	–	–	﹤0.01%	846
2021 Q4	$0	Hold	3	–	–	﹤0.01%	862
2021 Q3	$0	Hold	3	–	–	﹤0.01%	867
2021 Q2	$0	Hold	3	–	–	﹤0.01%	861
2021 Q1	$0	Buy	+3	New	+$164	﹤0.01%	865

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

DSC

Duncker Streett & Co St. Louis, Missouri $526M AUM 22.2% 1-Year Est. Return

Montag & Associates's BBC Position: Q4 2022 in Review

Montag & Associates sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q4 2022, closing a stake of 3 shares.

Montag & Associates first reported a position in BBC in Q1 2021 and held it in 7 quarters. The position peaked at $0 in Q3 2022. 19 funds tracked by Wall St. Rank hold BBC as of Q4 2022.

Montag & Associates reported no remaining Virtus Biotech Clinical Trials ETF position as of Q4 2022 after selling out during the quarter.
Montag & Associates sold 3 Virtus Biotech Clinical Trials ETF shares in Q4 2022.
Montag & Associates first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2021 and held it in 7 quarters.
Montag & Associates's Virtus Biotech Clinical Trials ETF position peaked at $0 in Q3 2022.
19 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q4 2022.

Based on Montag & Associates's 13F filing for Q4 2022, filed 2 Feb 2023.